The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis

Autor: Dominika Klimczak-Tomaniak, Jolanda J.C. Voermans, Stefan Roest, Jasper J. Brugts, Kadir Caliskan, Alina A. Constantinescu, Olivier C. Manintveld, Felix Zijlstra, Jeroen J. A. van Kampen, Isabella Kardys
Přispěvatelé: Cardiology, Virology
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Graft Rejection
Male
medicine.medical_treatment
Biopsy
Cytomegalovirus
Coronary Artery Disease
030230 surgery
Coronary Angiography
Gastroenterology
0302 clinical medicine
Postoperative Complications
Interquartile range
Risk Factors
Clinical endpoint
Prevalence
Medicine
Valganciclovir
Heart transplantation
Hazard ratio
virus diseases
Immunosuppression
Heart
Original Clinical Science—General
Middle Aged
Allografts
Coronary Vessels
Treatment Outcome
Cytomegalovirus Infections
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
030211 gastroenterology & hepatology
Female
Immunosuppressive Agents
medicine.drug
Adult
medicine.medical_specialty
Congenital cytomegalovirus infection
Antiviral Agents
03 medical and health sciences
Internal medicine
Humans
Retrospective Studies
Transplantation
business.industry
Myocardium
Breakthrough infection
Antibiotic Prophylaxis
medicine.disease
Heart Transplantation
business
Zdroj: Transplantation, 104(7), 1508-1518. Lippincott Williams & Wilkins
Transplantation
ISSN: 0041-1337
DOI: 10.1097/tp.0000000000003015
Popis: Supplemental Digital Content is available in the text.
Background. Previous studies on the association between cytomegalovirus (CMV) infection and cardiac allograft vasculopathy (CAV) were conducted on patients transplanted in the prevalganciclovir prophylaxis era. The aim of our study is to evaluate this relation in heart transplantation (HTx) recipients treated according to current prophylactic and immunosuppressive regimens. Methods. This single-center retrospective study included all consecutive adult patients that underwent HTx between January 1, 2000, and May 31, 2018. Clinically relevant CMV infection was defined as either plasma CMV DNAemia ≥ 1000 IU/mL with/without clinical symptoms or
Databáze: OpenAIRE
Externí odkaz: